Background: The study was conducted to compare 5-year follow-up of levonorgestrel-releasing intrauterine system (LNG-IUS) or thermal balloon ablation (TBA) for the treatment of heavy menstrual bleeding (HMB).
Study Design: A prospective, randomized controlled trial comparing LNG-IUS (n=30) and TBA (n=28) was performed. Hysterectomy rates, hemoglobin level, bleeding pattern, well-being status and satisfaction rates were assessed. Comparisons between groups were performed by χ(2) test and by unpaired and paired t tests.
Results: After 5 years of follow-up, women treated with a TBA had higher rates of hysterectomy (24%) compared to the LNG-IUS group (3.7%) due to treatment failure (p=.039). Use of LNG-IUS resulted in higher mean hemoglobin (±SD) levels in comparison to the TBA group (14.1±0.3 vs 12.7±0.4 g/dL, p=.009). Menstrual blood loss was significantly higher in the TBA when compared to the LNG-IUS group (45.5% vs 0.0% p<.001). The psychological general well-being index scores were similar. Patient acceptability, perceived clinical improvement and overall satisfaction rates were significantly higher in women using LNG-IUS.
Conclusion: Five-year follow-up of HMB treatment with LNG-IUS was associated with higher efficacy and satisfaction ratings compared to TBA.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.contraception.2012.11.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cost-effectiveness of long-acting progestogens versus the combined oral contraceptives pill for preventing recurrence of endometriosis-related pain following surgery: an economic evaluation alongside the PRE-EMPT trial.
BMJ Open
December 2024
Health Economics Unit, Department of Applied Health Science, College of Medicine and Health, University of Birmingham, Birmingham, B15 2TT, UK
Objectives: To evaluate the cost-effectiveness of long-acting progestogens (LAP), including levonorgestrel-releasing intrauterine system (LNG-IUS) and depot-medroxyprogesterone acetate (DMPA), compared with the combined oral contraceptives pill (COCP) in preventing recurrence of endometriosis-related pain postsurgery.
Design: Within-trial economic evaluation alongside a multicentre, pragmatic, parallel-group, open-label, randomised controlled trial (Preventing Recurrence of Endometriosis by means of Long-Acting Progestogen Therapy trial).
Setting: Thirty-four UK hospitals recruiting participants from November 2015 to March 2019.
Continuation of the Levonorgestrel-Releasing Intrauterine Device Among Adolescents With Endometriosis.
J Pediatr Adolesc Gynecol
October 2024
Division of Adolescent/Young Adult Medicine, Boston Children's Hospital, Boston, Massachusetts.
Study Objective: To estimate the 1-year continuation rate of the levonorgestrel-releasing intrauterine device (LNG-IUD) in adolescents with endometriosis, and the frequency at which additional systemic hormonal treatment (HT) is utilized.
Methods: A retrospective cohort study was performed of patients aged 12-21 years who underwent laparoscopy for endometriosis and LNG-IUD insertion at a single tertiary care institution between 2018 and 2021.
Results: We evaluated 224 adolescents (mean age = 17.
Risk factors for the recurrence in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment.
Gynecol Oncol
December 2024
Department of Obstetrics and Gynecology, Research Institute of Medical Science, Konkuk University School of Medicine, 263Achasan-ro, Gwangjin-gu, Seoul 05030, Republic of Korea. Electronic address:
Article Synopsis
- The study focused on identifying risk factors for cancer recurrence in patients with early-stage endometrioid endometrial cancer who achieved complete response through fertility-sparing hormonal treatment.
- A retrospective analysis of 178 patients revealed that 79.8% achieved complete response, but 59.9% experienced recurrence during a median follow-up of 44 months.
- Key factors associated with higher recurrence risk included being older than 35 years and not becoming pregnant after achieving complete response, suggesting that these patients require close monitoring for potential recurrence.
Efficacy of drugs treatment in patients with endometrial hyperplasia with or without atypia: A systematic review and network meta-analysis.
Medicine (Baltimore)
September 2024
Department of Obstetrics and Gynecology, Women's Hospital Zhejiang University School of Medicine, Hangzhou, China.
Background: Endometrial hyperplasia (EH) is a hyperplastic endometrial lesion with irregular gland size, increased glands, and increased glandular interstitial ratio. During follow-up, some EH progressed further to endometrial cancer. It is crucial to provide timely treatment for EH and improve the overall prognosis of EH patients.
View Article and Find Full Text PDFPreventing recurrence of endometriosis-related pain by means of long-acting progestogen therapy: the PRE-EMPT RCT.
Health Technol Assess
September 2024
Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Article Synopsis
- Endometriosis affects 1 in 10 women, often leading to surgery for persistent pain, but symptoms frequently recur post-operation, creating uncertainty about the most effective hormonal treatments.
- A study was conducted across 34 UK hospitals to compare the effectiveness of long-acting progestogen therapy with the combined oral contraceptive pill in preventing pain recurrence and improving quality of life after surgery.
- Results showed both treatment options reduced pain compared to pre-surgery levels, but no significant difference in effectiveness was found between the two, although fewer follow-up procedures were needed for those on long-acting progestogen.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!